Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma
Antineoplastic Combined Chemotherapy Protocols
Lymphoma, T-Cell, Cutaneous
The addition of interferon alfa-2b did not increase the response rate that would have been expected with bexarotene alone.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency